The MALT1 locus and peanut avoidance in the risk for peanut allergy - 06/06/19
Doi : 10.1016/j.jaci.2019.02.016
Alexandra Winters, PhD a, Henry T. Bahnson, MPH b, c, Ingo Ruczinski, PhD d, Meher P. Boorgula, MS e, Claire Malley, MS a, Ali R. Keramati, MD a, Sameer Chavan, MS e, David Larson, PhD c, Karen Cerosaletti, PhD b, Peter H. Sayre, MD, PhD c, f, Marshall Plaut, MD g, George Du Toit, MB, BCh, FRCPCH h, Gideon Lack, MB, BCh, FRCPCH h, Kathleen C. Barnes, PhD e, Gerald T. Nepom, MD, PhD c, Rasika A. Mathias, ScD a 
for the
for the
Immune Tolerance Network LEAP Study Team
a Department of Medicine, Johns Hopkins University, Baltimore, Md
b Benaroya Research Institute, Seattle, Wash
c Immune Tolerance Network, San Francisco, Calif
d Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Md
e Department of Medicine, University of Colorado, Anschutz, Colo
f Department of Medicine, University of California, San Francisco, Calif
g Allergy, Asthma and Airway Biology Branch, Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, Bethesda, Md
h Department of Pediatric Allergy, Division of Asthma, Allergy and Lung Biology, King's College London, and Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
| This research was performed as a project of the Immune Tolerance Network, an international clinical research consortium headquartered at the Benaroya Research Institute, and supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award no. UM1AI109565. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. |
|
| Disclosure of potential conflict of interest: G. Lack reports holding stock and stock options in DBV Technologies. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2019
The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 143 - N° 6
P. 2326-2329 - juin 2019 Retour au numéro
Article précédent
- Gene expression signatures of circulating human type 1, 2, and 3 innate lymphoid cells
- Shuo Li, Hideaki Morita, Milena Sokolowska, Ge Tan, Tadech Boonpiyathad, Lennart Opitz, Keisuke Orimo, Stuart K. Archer, Kirstin Jansen, Mimi L.K. Tang, Damian Purcell, Magdalena Plebanski, Cezmi A. Akdis
- Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function
- Clare Hardman, Wentao Chen, Jian Luo, Paul Batty, Yi-Ling Chen, Janina Nahler, Yanqiu Wu, Ian D. Pavord, Veit J. Erpenbeck, David A. Sandham, Luzheng Xue, Graham Ogg
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?